Literature DB >> 15752584

Characterization of functional urotensin II receptors in human skeletal muscle myoblasts: comparison with angiotensin II receptors.

Jian-shen Qi1, Lisa K Minor, Charles Smith, Bing Hu, Jing Yang, Patricia Andrade-Gordon, Bruce Damiano.   

Abstract

The properties of urotensin II (U-II) receptor (UT receptor) and angiotensin II (ANG II) receptor (AT receptor) in primary human skeletal myoblasts (HSMM) and differentiated skeletal myotubes (HSMMT) were characterized. Radiolabeled U-II and ANG II bound specifically to HSMM with Kd's of 0.31 nM (2311 receptors/cell) and 0.61 nM (18,257 receptors/cell), respectively. The cyclic segment of U-II peptide, CFWKYC, was the minimal sequence required for binding, with the WKY residues essential. Inhibitor studies suggested AT1 is the predominant ANG II receptor. After radioligand binding, under conditions designed to minimize receptor internalization, half the bound U-II was resistant to acid washing suggesting that U-II binds tightly to its receptor in a quasi-irreversible fashion. The AT1 receptor-bound radioligand was completely removed under the same conditions. RT-PCR detected the expression of mRNAs for UT and AT1 receptors. Western blotting showed that U-II and ANG II signaled via ERK1/2 kinase. UT receptor was not lost upon differentiation into myotubes since both mRNA for UT receptor and U-II binding were still present. ANG II receptors were also present as shown by ANG II-induced calcium mobilization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15752584     DOI: 10.1016/j.peptides.2004.11.018

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  9 in total

1.  AT1 receptor blocker losartan protects against mechanical ventilation-induced diaphragmatic dysfunction.

Authors:  Oh Sung Kwon; Ashley J Smuder; Michael P Wiggs; Stephanie E Hall; Kurt J Sollanek; Aaron B Morton; Erin E Talbert; Hale Z Toklu; Nihal Tumer; Scott K Powers
Journal:  J Appl Physiol (1985)       Date:  2015-09-10

2.  An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle.

Authors:  Isao Murakami; Takamasa Takeuchi; Mayuyo Mori-Uchino; Seiichiro Mori; Takuma Fujii; Daisuke Aoki; Keiichi Nakagawa; Tadahito Kanda
Journal:  Mol Biotechnol       Date:  2011-09       Impact factor: 2.695

3.  Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.

Authors:  Wei Song; John McDonald; Valeria Camarda; Girolamo Calo; Remo Guerrini; Erika Marzola; Jonathan P Thompson; David J Rowbotham; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-05       Impact factor: 3.000

4.  Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation.

Authors:  Sheila M Gardiner; Julie E March; Philip A Kemp; Janet J Maguire; Rhoda E Kuc; Anthony P Davenport; Terence Bennett
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

5.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 6.  Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia.

Authors:  Tadashi Yoshida; A Michael Tabony; Sarah Galvez; William E Mitch; Yusuke Higashi; Sergiy Sukhanov; Patrice Delafontaine
Journal:  Int J Biochem Cell Biol       Date:  2013-06-13       Impact factor: 5.085

7.  Angiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivo.

Authors:  Weidong Chai; Wenhui Wang; Zhenhua Dong; Wenhong Cao; Zhenqi Liu
Journal:  Diabetes       Date:  2011-09-06       Impact factor: 9.461

8.  Angiotensin-II Drives Human Satellite Cells Toward Hypertrophy and Myofibroblast Trans-Differentiation by Two Independent Pathways.

Authors:  Annunziatina Laurino; Valentina Spinelli; Manuela Gencarelli; Valentina Balducci; Leonardo Dini; Lorenzo Diolaiuti; Marco Ghionzoli; Antonio Messineo; Alessandro Mugelli; Elisabetta Cerbai; Laura Raimondi; Laura Sartiani
Journal:  Int J Mol Sci       Date:  2019-10-03       Impact factor: 5.923

9.  Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours.

Authors:  Benjamin Poret; Laurence Desrues; Marc-André Bonin; Martin Pédard; Martine Dubois; Richard Leduc; Romain Modzelewski; Pierre Decazes; Fabrice Morin; Pierre Vera; Hélène Castel; Pierre Bohn; Pierrick Gandolfo
Journal:  Biomolecules       Date:  2020-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.